文献速递炎症性肠病

儿童克罗恩病诱导后较高的英夫利西单抗浓度与良好临床结局相关:REACH 试验的事后分析

Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn's Disease: A Post Hoc Analysis of the REACH Trial.
PubMed 文献 · Am J Gastroenterol · 2022-12-23

该研究为 REACH 试验的事后分析,纳入 103 例接受英夫利西单抗治疗的中重度儿童克罗恩病患者,评估诱导期及诱导后早期英夫利西单抗浓度与短期及长期临床结局的关联。多因素分析显示,第 10 周英夫利西单抗浓度较高与第 10 周临床缓解及第 30 周长期临床应答独立相关。

要点

  • 第 10 周英夫利西单抗浓度较高与第 10 周临床缓解独立相关(OR 1.54)。
  • 第 10 周英夫利西单抗浓度较高与第 30 周长期临床应答独立相关(OR 1.62)。
  • 第 10 周英夫利西单抗浓度阈值 ≥7.1 μg/mL 与第 10 周临床缓解相关。

核心结论

  • 儿童克罗恩病患者诱导后较高的英夫利西单抗浓度与短期和长期良好临床结局相关。

研究设计与样本

  • REACH 试验的事后分析,纳入 103 例接受英夫利西单抗治疗的中重度儿童克罗恩病患者。

主要发现

  • 多因素 logistic 回归分析显示,第 10 周英夫利西单抗浓度较高与第 10 周临床缓解独立相关(OR 1.54;95%CI 1.06-2.22;P=0.022)。
  • 多因素 logistic 回归分析显示,第 10 周英夫利西单抗浓度较高与第 30 周长期临床应答独立相关(OR 1.62;95%CI 1.12-2.36;P=0.010)。
  • 受试者工作特征分析确定第 10 周英夫利西单抗浓度阈值 ≥7.1 μg/mL 与第 10 周临床缓解相关。
  • 受试者工作特征分析确定第 10 周英夫利西单抗浓度阈值 ≥6.5 μg/mL 与第 30 周长期临床应答相关。

关键数值与推荐

  • 早期临床缓解定义为第 10 周儿童克罗恩病活动指数评分 ≤10。
  • 长期临床应答定义为第 30 周和第 54 周儿童克罗恩病活动指数评分较基线下降至少 15 分,总分 ≤30 且无需停药。
  • 第 10 周英夫利西单抗浓度阈值 ≥7.1 μg/mL 与第 10 周临床缓解相关。
  • 第 10 周英夫利西单抗浓度阈值 ≥6.5 μg/mL 与第 30 周长期临床应答相关。

临床怎么用

  • 作者认为,在诱导期调整剂量以达到更高的英夫利西单抗暴露可能使儿童克罗恩病患者获得更好的结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Exposure-outcome relationship data show that higher infliximab concentrations are associated with better outcomes in patients with Crohn's disease (CD). However, most of these data were derived from adult patients on maintenance therapy. We aimed to investigate the association of infliximab concentrations during and early after induction therapy of infliximab with short-term and long-term clinical outcomes in a pediatric CD population. METHODS: We conducted a post hoc analysis of the REACH trial which included pediatric patients with moderate-to-severe CD treated with infliximab (n = 103). The investigated outcomes were early clinical remission (CR) defined as a pediatric CD activity index score of ≤ 10, assessed at week 10, and long-term clinical response (LTCR) defined as a decrease from baseline in the pediatric CD activity index score of at least 15 points, with a total score of ≤ 30 and no need for drug discontinuation, assessed at weeks 30 and 54. RESULTS: Based on multivariable logistic regression analysis, higher week 10 infliximab concentrations were independently associated with CR at week 10 (odds ratio: 1.54; 95% confidence interval: 1.06-2.22; P = 0.022) and LTCR at week 30 (odds ratio: 1.62; 95% confidence interval: 1.12-2.36; P = 0.010). Receiver operating characteristic analysis identified week 10 infliximab concentration thresholds of ≥7.1 μg/mL and ≥6.5 μg/mL to be associated with CR at week 10 and LTCR at week 30, respectively. DISCUSSION: Higher postinduction infliximab concentrations are associated with both short-term and long-term favorable clinical outcomes in pediatric patients with CD. Tailoring dosing during induction to achieve higher infliximab exposure may lead to better outcomes in pediatric patients with CD.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Cheifetz AS, Vande Casteele N, Wang Z, et al. Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn's Disease: A Post Hoc Analysis of the REACH Trial. Am J Gastroenterol. 2022. PMID: 36624036. doi:10.14309/ajg.0000000000002096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。